Equillium Management

Management criteria checks 3/4

Equillium's CEO is Bruce Steel, appointed in Jan 2006, has a tenure of 18.83 years. total yearly compensation is $1.35M, comprised of 33.8% salary and 66.2% bonuses, including company stock and options. directly owns 10.48% of the company’s shares, worth $2.89M. The average tenure of the management team and the board of directors is 6.7 years and 6.2 years respectively.

Key information

Bruce Steel

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage	33.8%
CEO tenure	18.8yrs
CEO ownership	10.5%
Management average tenure	6.7yrs
Board average tenure	6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bruce Steel's remuneration changed compared to Equillium's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$1m	US$455k	-US$13m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$455k	-US$62m
Sep 30 2022	n/a	n/a	-US$76m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$2m	US$440k	-US$39m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$31m
Dec 31 2020	US$782k	US$198k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$27m
Dec 31 2019	US$1m	US$396k	-US$26m
Sep 30 2019	n/a	n/a	-US$23m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$452k	US$219k	-US$13m

Compensation vs Market: Bruce's total compensation ($USD1.35M) is above average for companies of similar size in the UK market ($USD354.57K).

Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.

CEO

Bruce Steel (58 yo)

18.8yrs

Tenure

US$1,348,215

Compensation

Mr. Bruce D. Steel, CFA has been Chief Executive Officer of Equillium, Inc. since January 1, 2020. He has been a Managing Director at BioMed Ventures LP since September 2010. Mr. Steel serves as President...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel Bradbury	Executive Chairman	7.7yrs	US$267.30k	5.29% $ 1.5m
Bruce Steel	Co-Founder	18.8yrs	US$1.35m	10.48% $ 2.9m
Christine Zedelmayer	Senior VP & COO	6.8yrs	US$785.51k	0.38% $ 105.5k
Stephen Connelly	Chief Scientific Officer & Director	6.8yrs	US$827.25k	2.8% $ 774.4k
Jason Keyes	Chief Financial Officer	6.7yrs	no data	0.34% $ 94.9k
Penny Tom	Senior VP of Finance & Principal Accounting Officer	no data	no data	0.018% $ 5.1k
Michael Moore	Vice President of Investor Relations & Corporate Communications	no data	no data	no data
Matthew Ritter	Senior Vice President of Corporate Development	4.5yrs	no data	no data
Joel Rothman	Chief Development Officer	4.9yrs	no data	0.16% $ 45.4k

6.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 0A4D's management team is seasoned and experienced (6.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel Bradbury	Executive Chairman	7.7yrs	US$267.30k	5.29% $ 1.5m
Bruce Steel	Co-Founder	7.7yrs	US$1.35m	10.48% $ 2.9m
Stephen Connelly	Chief Scientific Officer & Director	7.7yrs	US$827.25k	2.8% $ 774.4k
Martha Demski	Independent Director	6.2yrs	US$98.77k	0.067% $ 18.6k
Bala Manian	Independent Director	7.5yrs	US$101.79k	0.067% $ 18.6k
Thomas Daniel	Member of Scientific & Clinical Advisory Board	5.5yrs	no data	no data
Mark Pruzanski	Independent Director	6.2yrs	US$83.77k	0.067% $ 18.6k
Vijay Kuchroo	Member of Scientific & Clinical Advisory Board	no data	no data	no data
Barbara Troupin	Independent Director	2.8yrs	US$65.25k	0% $ 0
Charles McDermott	Independent Director	6.2yrs	US$60.69k	0.067% $ 18.6k
Fred Ramsdell	Member of Scientific & Clinical Advisory Board	no data	no data	no data
Yu Xu	Independent Director	3.8yrs	US$74.86k	0% $ 0

6.2yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 0A4D's board of directors are considered experienced (6.2 years average tenure).

Equillium Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

New major risk - Financial position

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

New minor risk - Profitability

Forecast to breakeven in 2024

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Insufficient new directors

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Insufficient new directors

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Insufficient new directors

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

High number of new directors

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

High number of new directors

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Forecast to breakeven in 2025

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

Equillium, Inc. Appoints Yu (Katherine) Xu, Ph.D., as A Class II Director

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 2000 Dynamic Index

Equillium, Inc. Appoints Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer, Effective January 11, 2021

Equillium Announces Positive Interim Data of Itolizumab in the First-Line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age